Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.

Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.